Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit won’t be answered until Phase 3 tests read out.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback